{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:13:05Z","timestamp":1786993985354,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.mayocp.2017.05.023","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T08:01:22Z","timestamp":1501574482000},"page":"1203-1213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation"],"prefix":"10.1016","volume":"92","author":[{"given":"Micha\u0142","family":"Mazurek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Shantsila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mayocp.2017.05.023_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"10046","key":"10.1016\/j.mayocp.2017.05.023_bib2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"Lancet"},{"issue":"38","key":"10.1016\/j.mayocp.2017.05.023_bib4","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in\u00a0collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.mayocp.2017.05.023_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A\u00a0prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.mayocp.2017.05.023_bib6","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1161\/CIRCOUTCOMES.114.001556","article-title":"Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? the prospective global anticoagulant registry in the FIELD-Atrial Fibrillation","volume":"8","author":"Lip","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"10.1016\/j.mayocp.2017.05.023_bib7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjmed.2015.07.013","article-title":"Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: The GLORIA-AF Registry, phase II","volume":"128","author":"Huisman","year":"2015","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2017.05.023_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.amjmed.2016.09.012","article-title":"Registries in atrial fibrillation: from trials to real-life clinical practice","volume":"130","author":"Mazurek","year":"2017","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2017.05.023_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1160\/TH13-05-0424","article-title":"Evaluation of patients\u2019 attitudes towards stroke prevention and bleeding risk in atrial fibrillation","volume":"111","author":"LaHaye","year":"2014","journal-title":"Thromb Haemost"},{"issue":"16","key":"10.1016\/j.mayocp.2017.05.023_bib10","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/heartjnl-2012-303472","article-title":"The use of anticoagulants in the management of atrial fibrillation among general practices in England","volume":"99","author":"Cowan","year":"2013","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.mayocp.2017.05.023_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ageing\/afv071","article-title":"Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice","volume":"44","author":"Wolff","year":"2015","journal-title":"Age Ageing"},{"issue":"7","key":"10.1016\/j.mayocp.2017.05.023_bib12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/europace\/euv068","article-title":"Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation","volume":"17","author":"Camm","year":"2015","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.mayocp.2017.05.023_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.mayocp.2016.03.007","article-title":"Impact on outcomes of changing treatment guideline recommendations for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"91","author":"Chao","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.mayocp.2017.05.023_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ahj.2007.03.008","article-title":"Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation: the Euro Heart Survey on Atrial Fibrillation","volume":"153","author":"Nieuwlaat","year":"2007","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.mayocp.2017.05.023_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1378\/chest.10-2436","article-title":"Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project","volume":"140","author":"Gorin","year":"2011","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.mayocp.2017.05.023_bib16","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/europace\/euv269","article-title":"Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry","volume":"17","author":"Lip","year":"2015","journal-title":"Europace"},{"issue":"11","key":"10.1016\/j.mayocp.2017.05.023_bib17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00392-016-0999-4","article-title":"Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study","volume":"105","author":"Proietti","year":"2016","journal-title":"Clin Res Cardiol"},{"issue":"630","key":"10.1016\/j.mayocp.2017.05.023_bib18","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.3399\/bjgp15X683113","article-title":"Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort","volume":"65","author":"Shantsila","year":"2015","journal-title":"Br J Gen Pract"},{"issue":"2","key":"10.1016\/j.mayocp.2017.05.023_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.mayocp.2017.05.023_bib20","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1001\/jama.2015.4369","article-title":"Stroke prevention in atrial fibrillation: a systematic review","volume":"313","author":"Lip","year":"2015","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.mayocp.2017.05.023_bib21","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jacc.2015.01.044","article-title":"Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score","volume":"65","author":"Lip","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.mayocp.2017.05.023_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.05.023_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","article-title":"Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1","volume":"65","author":"Friberg","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.05.023_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"10.1016\/j.mayocp.2017.05.023_bib25","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.amjmed.2016.03.024","article-title":"Major outcomes in atrial fibrillation patients with one risk factor: impact of time in therapeutic range observations from the SPORTIF trials","volume":"129","author":"Proietti","year":"2016","journal-title":"Am J Med"},{"issue":"38","key":"10.1016\/j.mayocp.2017.05.023_bib26","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"37","author":"Bassand","year":"2016","journal-title":"Eur Heart J"},{"issue":"46","key":"10.1016\/j.mayocp.2017.05.023_bib27","first-page":"3265","article-title":"Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors","volume":"36","author":"Lip","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.mayocp.2017.05.023_bib28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1160\/TH13-07-0552","article-title":"Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial","volume":"110","author":"Apostolakis","year":"2013","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.mayocp.2017.05.023_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pcad.2015.07.003","article-title":"Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk","volume":"58","author":"Potpara","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2017.05.023_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jgs.13200","article-title":"Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude","volume":"63","author":"Bahri","year":"2015","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.mayocp.2017.05.023_bib31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.mayocp.2017.05.023_bib32","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2013developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617304044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617304044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T16:58:16Z","timestamp":1535561896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619617304044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0025619617304044"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.05.023","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}